Bio Roundup: Alzheimer’s Puzzle, ESMO Assessed, Drug Prices & More
Summary
As with another Alzheimer’s meeting back in July , much of the interest there focused on data from a drug developed by Japanese pharmaceutical company Eisai and partner Biogen that has left some scientists and investors puzzled.—The European Society of Medical Oncology’s annual meeting came and went this past week, and Xconomy rounded up the key headlines, which included immunotherapy advances in breast and lung cancer and a brewing battle among two developers aiming for “tissue agnostic” drug approvals.—Bristol-Myers Squibb (NYSE: BMY ) disclosed another setback to its immunotherapy strategy in lung cancer, as the FDA extended , by three months, a review of a two-drug regimen the company has been touting for the disease.—Synergy Pharmaceuticals (NASDAQ: SGYP ) shares plunged 66 percent after the company said it hasn’t found a buyer or come to a deal with its lender, CRG Servicing, to avoid defaulting on its debt.—Synthego of Menlo Park, CA, raised $110 million in a Series C round to expand its gene-editing toolkit business, particularly its “Engineered Cells” product, in which Synthego uses CRISPR to produce custom-edited cells for researchers.
Classifications
AskAI Classifications
LabelsLinked Companies
